S&P Capital IQ Initiates Coverage on VentriPoint Diagnostics Ltd in Standard & Poor’s Factual Stock Reports

S&P Capital IQ announced today that it has commenced Standard & Poor’s Factual Stock Report coverage on VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd. (OTCQX: VPTDF; TSXV: VPT) is a medical device company engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. By using images produced from existing medical imaging systems, VentriPoint's system generates functional heart measurements and a three-dimensional (3D) model of the heart. Clinically, measuring ventricular volume and function is fundamental in evaluating patients to determine the severity of their disease and in assessing the effectiveness of treatment, in gauging prognosis and in deciding the timing of surgical and pharmacological intervention. The clinical challenge is to accurately measure the volume in the right ventricle, which Ventripoint has overcome at both a lower cost and improved efficiency than current clinical practice.

VentriPoint Diagnostics Ltd. has both CE and Health Canada approval to market its first application for the treatment of Tetralogy of Fallot. On March 29, 2012 the Company announced that it has received CE Approval for the its new Pulmonary Arterial Hypertension (PAH) application for the VentriPoint Medical SystemTM (VMSTM). Easier than Magnetic Resonance Imaging (MRI) and safer than catheterization, without sacrificing accuracy, the VMS enables repeated monitoring of the right ventricle that ensures patients receive appropriate treatment. Sales and marketing of the PAH application in Europe will commence immediately.

VentriPoint’s VMS heart analysis system is fast, accurate and non-invasive. The VMS technique benefits patients who cannot lie flat and still for up to an hour to undergo an MRI; patients with severe PAH must lie at an angle or sit up to avoid fluid buildup in their lungs, and some pediatric patients must be sedated to avoid movement during an MRI procedure . Furthermore, when using the VentriPoint system there is no need for catheterization, an invasive and frequently risky procedure. “Securing approval to market our PAH application in Europe is an important milestone for the Company. I am very pleased that we can respond to growing demand among prospective customers in the European markets,” said Dr. George Adams, President and CEO of VentriPoint.

VentriPoint operates in Seattle, Washington, and was founded in 2004.

Standard & Poor’s Factual Stock Report coverage on VentriPoint Diagnostics Ltd. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.ventripoint.com for additional information.

About Standard & Poor's Factual Stock Reports

Currently profiling over 500 issuers, Standard & Poor’s Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor’s Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a brand of the McGraw-Hill Companies (NYSE:MHP), is a leading provider of multi-asset class data, research and analytics to institutional investors, investment advisors and wealth managers around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Securities Evaluations, Global Data Solutions, and Compustat; and research offerings including Leveraged Commentary & Data, Global Market Intelligence, and company and fund research, S&P Capital IQ sharpens financial intelligence into the wisdom today’s investors need.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50227989&lang=en

VentriPoint Diagnostics (QB) (USOTC:VPTDF)
過去株価チャート
から 12 2024 まで 1 2025